ATE444309T1 - Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper - Google Patents

Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper

Info

Publication number
ATE444309T1
ATE444309T1 AT01957479T AT01957479T ATE444309T1 AT E444309 T1 ATE444309 T1 AT E444309T1 AT 01957479 T AT01957479 T AT 01957479T AT 01957479 T AT01957479 T AT 01957479T AT E444309 T1 ATE444309 T1 AT E444309T1
Authority
AT
Austria
Prior art keywords
immunotherapy
myelocytic leukemia
antibodies
naked anti
cronic
Prior art date
Application number
AT01957479T
Other languages
English (en)
Inventor
David Goldenberg
Hans Hansen
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of ATE444309T1 publication Critical patent/ATE444309T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT01957479T 2000-08-08 2001-08-08 Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper ATE444309T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22369800P 2000-08-08 2000-08-08
PCT/US2001/024691 WO2002012347A1 (en) 2000-08-08 2001-08-08 Immunotherapy for chronic myelocytic leukemia

Publications (1)

Publication Number Publication Date
ATE444309T1 true ATE444309T1 (de) 2009-10-15

Family

ID=22837639

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01957479T ATE444309T1 (de) 2000-08-08 2001-08-08 Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper

Country Status (10)

Country Link
US (2) US6759045B2 (de)
EP (1) EP1309627B1 (de)
JP (1) JP3888971B2 (de)
CN (1) CN1468259A (de)
AT (1) ATE444309T1 (de)
AU (1) AU7921701A (de)
CA (1) CA2418014C (de)
DE (1) DE60140063D1 (de)
DK (1) DK1309627T3 (de)
WO (1) WO2002012347A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275540B1 (de) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Verfahren zur Steuerung der Aktivität von immunologisch funktionellen Molekülen
US20040071726A1 (en) * 2000-09-12 2004-04-15 Chicz Roman M Peptide epitopes recognized by antigen specific cd4lymphocytes
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2003050257A2 (en) * 2001-12-06 2003-06-19 University Of Florida Targeting leukemia cells
CA2481304A1 (en) * 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
WO2004043461A1 (en) * 2002-11-06 2004-05-27 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
NZ543635A (en) * 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
US7939058B2 (en) 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
DE602004029934D1 (de) 2003-12-04 2010-12-16 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
CA2561073C (en) * 2004-03-27 2014-01-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Composition and method for cancer treatment
US7977320B2 (en) * 2004-10-29 2011-07-12 The Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
US20060234959A1 (en) * 2005-04-14 2006-10-19 Advanced Photodynamic Technologies, Inc. Photodynamic therapy utilizing multiple duty cycle light modulation
US20060257317A1 (en) * 2005-05-04 2006-11-16 Duke University Combination therapy in the treatment of cancer
EP1962913B1 (de) * 2005-11-30 2013-12-04 Therapharm GmbH Radioimmunokonjugat für humanes cd66 zur behandlung von multiplem myelom
US8298544B2 (en) * 2006-02-27 2012-10-30 Gal Markel CEACAM based antibacterial agents
JP5160412B2 (ja) * 2006-04-13 2013-03-13 株式会社医学生物学研究所 融合パートナー細胞
US20110038856A1 (en) * 2006-11-02 2011-02-17 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
WO2011034660A1 (en) * 2009-09-16 2011-03-24 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
MX363787B (es) 2013-03-13 2019-04-03 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de los mismos.
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
EP3193940A1 (de) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepine und konjugate daraus
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017210621A1 (en) 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
IL136051A0 (en) * 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US6491917B1 (en) * 1998-07-31 2002-12-10 Stemcell Technologies Inc. Antibody composition for debulking blood and bone marrow samples from CML patients

Also Published As

Publication number Publication date
WO2002012347A1 (en) 2002-02-14
CA2418014A1 (en) 2002-02-14
EP1309627B1 (de) 2009-09-30
DK1309627T3 (da) 2009-12-21
US20020022031A1 (en) 2002-02-21
US20040213796A1 (en) 2004-10-28
DE60140063D1 (de) 2009-11-12
CN1468259A (zh) 2004-01-14
JP2004505994A (ja) 2004-02-26
JP3888971B2 (ja) 2007-03-07
CA2418014C (en) 2014-01-21
US6759045B2 (en) 2004-07-06
US7323168B2 (en) 2008-01-29
AU2001279217C1 (en) 2002-02-18
AU7921701A (en) 2002-02-18
EP1309627A1 (de) 2003-05-14

Similar Documents

Publication Publication Date Title
DE60140063D1 (de) Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper
MXPA05005726A (es) Metodos y composiciones para inducir apoptosis en celulas de cancer.
MA42999B1 (fr) Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë
MX2021007350A (es) Terapia combinada de cd70 y venetoclax, un inhibidor de bcl-2, para tratar la leucemia mieloide aguda.
CL2007001624A1 (es) Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular.
CL2012000519A1 (es) Uso de un anticuerpo aislado o fragmento de enlace antígeno del mismo que comprende una región variable de cadena ligera y una de cadena pesada (sec nº38 y nº40) útil en el tratamiento y prevención de carcinoma de células escamosas en un mamífero (div. sol. 3615-07).
TW200612918A (en) Lonidamine analogs
IL184617A (en) Antibody against dr5 that includes mutations in the heavy and light chain of the full-length antibody 16e2 and various aspects related to this antibody
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
MA43000B1 (fr) Polythérapie pour le traitement de tumeurs malignes
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
AR023616A1 (es) Preparaciones combinadas que comprenden derivados de antraciclina
BR0306820A (pt) Uso de inibidores cox-2 em combinação com agentes antivirais para o tratamento de infecções de papilomavìrus
HRPK20041072B3 (hr) Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
WO2008112129A3 (en) Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
MXPA02007899A (es) Citoquinas modificadas para utilizarse en terapia de cancer.
MY157366A (en) Therapies and compositions comprising cathepsin s antibodies
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
WO2008066854A3 (en) Methods and compositions for inducing apoptosis in cancer cells
AU2021334165A8 (en) Method of treatment of patients having reduced sensitivity to a BCL-2 inhibitor
ATE509630T1 (de) Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern
GT200000194A (es) Quimioterapia de combinacion.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties